论文部分内容阅读
目的:用Meta分析的方法定量评价干扰素辅助治疗肝癌的效果。方法:计算机检索EMbase、PubMed、Cochrane图书馆、中国生物医学文献数据库、中国期刊全文数据库(CNKI)、维普中文科技期刊数据库,收集有关干扰素辅助治疗肝癌的随机对照试验(randomized controlled trial,RCT),两名评价者单独评价纳入研究的方法学质量并提取资料,用Cochrane协作网提供的RevMan5.0软件进行Meta分析。结果:共纳入8篇RCTs,共计836例患者。Meta分析结果显示,肝癌患者接受基础治疗后,干扰素辅助治疗组在复发率方面与安慰剂组相比,差异有统计学意义[RR=0.86,95%CI(0.77,0.96),P<0.05];两组在病死率方面的差异也有统计学意义[RR=0.64,95%CI(0.54,0.76),P<0.05]。结论:干扰素辅助治疗可以降低肝癌患者的病死率和复发率,但远期疗效尚待大样本、高质量的RCTs进一步证实。
Objective: To quantitatively evaluate the effect of interferon adjuvant treatment of liver cancer by Meta-analysis. METHODS: Randomized controlled trials (RCTs) of interferon-assisted hepatocellular carcinoma (HCC) patients were collected from EMbase, PubMed, Cochrane Library, Chinese Biomedical Literature Database, Chinese Journal Full-text Database (CNKI) Two reviewers independently assessed the methodological quality of the included studies and extracted data for Meta-analysis using RevMan 5.0 software provided by the Cochrane Collaboration. Results: A total of 8 RCTs were enrolled for a total of 836 patients. Meta-analysis showed that there was significant difference in relapse rate between interferon adjuvant therapy group and placebo group after receiving basic treatment [RR = 0.86,95% CI (0.77, 0.96), P <0.05 ]. There was also a statistically significant difference in mortality between the two groups (RR = 0.64, 95% CI (0.54, 0.76), P <0.05]. Conclusion: Interferon adjuvant therapy can reduce the mortality and recurrence rate of patients with liver cancer, but the long-term efficacy of large samples yet to be further confirmed by high-quality RCTs.